Using proteomics to advance understanding of alzheimer’s disease
Using proteomics to advance
understanding of alzheimer’s disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
You’ll learn how mass spectrometry-based proteomics provides insights into brain changes and assists biomarker discovery in cerebrospinal fluid and plasma, and discover the potential of affinity-based proteomics for reliable biomarker identification. Our expert speaker will delve into intricate networks like proteostasis and the matrisome, highlighting their implications for therapeutic development.
Attend this webinar to:
- Gain insights into the landscape of AD brain changes using unbiased mass spectrometry-based proteomics
- Learn about biomarker discovery in AD cerebrospinal fluid and plasma through multi-platform proteomic analysis
- Understand the potential of affinity-based proteomics, including modified aptamer technology, in identifying reliable biomarkers for AD
- Explore the intricate networks associated with AD pathology and their implications for therapeutic development
Erik Johnson, MD, PhD
Assistant Professor, Department of Neurology
Emory University
Erik Johnson, MD, PhD, is an Assistant Professor in the Department of Neurology and a member of the Goizueta Alzheimer’s Disease Research Center and Center for Neurodegenerative Diseases at Emory University. He is a cognitive neurologist with an active clinical practice who sees patients with Alzheimer’s disease and other cognitive disorders. His research interests focus on using proteomics to understand the biochemical mechanisms that underlie Alzheimer’s disease and to develop molecular fluid biomarkers for these pathological changes. He is actively involved in large consortium research efforts on AD including the Accelerating Medicine Partnership – Alzheimer’s Disease (AMP-AD) consortium and the Dominantly Inherited Alzheimer Disease (DIAN) consortium.
Using proteomics to advance understanding of alzheimer’s disease
A presentation by Erik Johnson, MD, PhD
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.
WebinarDetecting growing tumors through changes in the plasma proteome
In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.